Vivus Will Cut Population In Qnexa Resubmission
This article was originally published in The Pink Sheet Daily
Executive Summary
The biotech announces it will resubmit its obesity drug by the end of October, two months ahead of schedule, after a meeting with FDA.
You may also be interested in...
Regulatory Update For Qnexa Could Signal A Change In The Obesity Landscape
New developments for Vivus’ weight loss drug Qnexa may mean that the regulatory environment for obesity treatments could be improving.
Regulatory Update For Qnexa Could Signal A Change In The Obesity Landscape
New developments for Vivus’ weight loss drug Qnexa may mean that the regulatory environment for obesity treatments could be improving.
Vivus Resubmits Qnexa, But Limits Its Market Opportunity
The biotech once again submits its application to FDA for its obesity drug, but the upside potential is drastically cut.